Citations

Clear

3042 citation(s) found for "Kumar, S".

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Kumar, Shaji , Rees, Matthew J. , D’Agostino, Mattia , Leypoldt, Lisa Beatrice , Weisel, Katja C , Gay, Francesca

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 21, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1200/edbk_433520 | PMID 38772002 Get It

Despite significant improvement in the outcomes of patients with newly diagnosed multiple myeloma (NDMM) with novel therapies, there is still an underserved high-risk (HR) population that experiences early disease progression and death. With the median survival crossing 10 years, we defined ultrahigh-risk (uHR)MM as MM leading to death within 24-36 months of diagnosis and HRMM as MM leading to death within 36-60 months. Several features have emerged as markers of uHRMM: the co-occurrence of two or more high-risk cytogenetic abnormalities, extramedullary disease, plasma cell leukemia and a high-risk gene expression profiling signature. The heterogeneous risk definition across trials, the few trials available designed for HR patients, and the small HR subgroups in all-comers trials make it difficult to generate recommendations with high levels of evidence. Nevertheless, regardless of treatment administered, several studies consistently showed that achieving and maintaining measurable residual disease negativity is now considered the main factor able to mitigate the adverse prognosis related to baseline features. For fit patients with HR transplant-eligible (TE) NDMM, quadruplet induction/consolidation treatment with anti-CD38 monoclonal antibodies, immunomodulatory agents, proteasome inhibitors and dexamethasone, and autologous stem-cell transplant and maintenance with, if available, at least a doublet combination could be considered the option of choice. For non-TE NDMM, considering the recent data generated and carefully reviewing those upcoming, quadruplet treatment consisting of anti-CD38 monoclonal antibodies, immunomodulatory agents, proteasome inhibitors, and dexamethasone should also be considered. Future trials integrating BCMA-directed novel generation immunotherapies hold great potential for further advancing the treatment landscape in all NDMM patients with HR disease.
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion
Watt, Kymberly D., Rolak, Stacey , Foley, David P. , Plichta, Jennifer K. , Pruthi, Sandhya , Farr, Deborah , Zwald, Fiona O. , Sanger, Cristina B. , Ricciardi, Rocco , Chang, George J. , Dizon, Don S. , Teoh, Deanna , Al‐Qaoud, Talal , Eggener, Scott E. , Kennedy, Cassie C. , D’Cunha, Jonathan, Mohindra, Nisha , Stewart, Shelby , Habermann, Thomas, Lunning, Matthew A. , Shah, Nirav N. , Mehta, Jayesh, Verna, Elizabeth C. , Hammel, Laura L., Al‐Adra, David , D'Cunha, Jonathan, Habermann, Thomas H, Kennedy, Cassie C , Plichta, Jennifer K , Carvajal, Richard D. , Dudek, Arkadiusz Z. , Langstraat, Carrie , Agarwal, Piyush Kumar , Schuster, Stephen J. , Gertz, Morie A. , Suvannasankha, Attaya , Farr, Maryjane , Blosser, Christopher D.

Mayo Clinic

Transplantation | May 21, 2024 | Volume: 108 | Issue: 12 | Pages: 2336-2350

10.1097/tp.0000000000005056 | PMID 38771067 Get It

With improved medical treatments, the prognosis for many malignancies has improved, and more patients are presenting for transplant evaluation with a history of treated cancer. Solid organ transplant (SOT) recipients with a prior malignancy are at higher risk of posttransplant recurrence or de novo malignancy, and they may require a cancer surveillance program that is individualized to their specific needs. There is a dearth of literature on optimal surveillance strategies specific to SOT recipients. A working group of transplant physicians and cancer-specific specialists met to provide expert opinion recommendations on optimal cancer surveillance after transplantation for patients with a history of malignancy. Surveillance strategies provided are mainly based on general population recurrence risk data, immunosuppression effects, and limited transplant-specific data and should be considered expert opinion based on current knowledge. Prospective studies of cancer-specific surveillance models in SOT recipients should be supported to inform posttransplant management of this high-risk population.
Dysregulated Cerebrospinal Fluid Proteome of Spinocerebellar Ataxia Type 2 and its Clinical Implications
Gajbhiye, Akshada , Bharadwaj, Sujas, Ghose, Vivek, Bellad, Anikha , Malo, Palash Kumar , Holla, Vikram V. , Hegde, Shantala , Bharath, Rose Dawn , Jain, Sanjeev , Yadav, Ravi , Pal, Pramod Kumar , Bharadwaj, Sujas , Holla, Vikram , Hegde, Shantala , Yadav, Ravi , Pal, Pramod Kumar , Bellad, Anikha , Stezin, Albert , Sathe, Gajanan , Saini, Jitender S. , Pandey, Akhilesh

Mayo Clinic

Movement Disorders | May 21, 2024 | Volume: 39 | Issue: 8 | Pages: 1418-1423

10.1002/mds.29834 | PMID 38769639 Get It

AbstractBackgroundAbnormalities in ataxin‐2 associated with spinocerebellar ataxia type 2 (SCA2) may lead to widespread disruptions in the proteome. This study was performed to identify dysregulated proteome in SCA2 and to explore its clinical‐radiological correlations.MethodsCerebrospinal fluid (CSF) samples from 21 genetically confirmed SCA2 were subjected to shotgun proteome analysis using mass spectrometry (MS) and tandem mass tag (TMT)‐based multiplexing. Proteins with at least 1.5‐fold change in abundance were identified. Their relative abundance was measured using parallel reaction monitoring (PRM) and correlated against disease‐related factors.ResultsEleven proteins were significantly upregulated in SCA2. They belonged to the family of cell adhesion molecules and granins. Their fold changes showed significant clinical, genetic, and radiological correlations.ConclusionsSignificant dysregulation of CSF proteome is seen in SCA2. The dysregulated protein may have potential use in clinical evaluation of patients with SCA2.
Vertebral Fracture Risk Is Increased Among Living Kidney Donors 25 Years After Donation: Survey-Based Study
Kasiske, Bertram L. , Matas, Arthur J. , Kremers, Hilal Maradit , Grossardt, Brandon R. , Kasiske, B.L. , Khosla, Sundeep , Kremers, Walter K. , Amer, Hatem , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 345-345

10.1681/asn.20233411s1345b Get It

Enhancement of In Vitro hPTH1-84 Bioactivity by hPTH38-84 and hPTH45-84
Losbanos, Louis, Hines, Jolaine M., Singh, Ravinder , Kritmetapak, Kittrawee , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 200-201

10.1681/asn.20213210s1200d Get It

Chemical Characterization and Quantitation of Circulating Intact Parathyroid Hormone and Parathyroid Hormone Fragments by High-Resolution Mass Spectrometry in Chronic Renal Failure
Losbanos, Louis, Hines, Jolaine M., O’Grady, Katherine , Vesper, Hubert W. , Kritmetapak, Kittrawee , Ulmer, Candice Z. , Enders, Felicity , Singh, Ravinder J. , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 158-158

10.1681/asn.20203110s1158a Get It

Hyperphosphatemia with Elevated Serum FGF-23 and PTH, Reduced Calcitriol, and Normal FGF7 Concentrations Characterizes Chronic Renal Failure in Humans
Losbanos, Louis, Berent, Taylor E. , Ashrafzadeh‐Kian, Susan , Hines, Jolaine M., Kritmetapak, Kittrawee , Algeciras‐Schimnich, Alicia , Singh, Ravinder J. , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 162-162

10.1681/asn.20203110s1162a Get It

Abstract P294: Age-Sex Differences in the Global Burden of Deaths and Disability Due to Cardiovascular Disease Attributable to Environmental Risk Factors and Its Trend From 1990-2019 in G20 Countries: A Benchmarking Analysis
Dadhania, Khush, Thota, Anjani Kumar, Gadamidi, Vinay Kumar , VEMPARALA, Priyatha, Parisapogu, Anusha, Patel, Juhi , MADHU, KRUPA, Desai, Hardik Dineshbhai , Vemparala, Priyatha, Alziadin, Nmair

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.p294 Get It

Background: Cardiovascular Disease (CVDs) is the leading cause of deaths amongst G20 countries accounting for 35.44% deaths in the G20 Countries. The G20 countries, being major economies, have a significant impact on global environmental conditions. Method: Using Global Burden of Disease tool, we estimated the deaths and Disability adjusted life years (DALYs) stratified by age, sex, year, and location due to CVD attributable to environmental risk factors across the G20 Countries from 1990-2019. Results: From 1990-2019, the annual percentage change showed a 37% rise in deaths, rising from 2,608,027-3,571,390. During the same period, DALYs surged by 25%, going from 63,297,319-78,964,495. However, when evaluating the age-standardized rates, both deaths and DALYs displayed a decrease from 1990 to 2019. In 2019, Saudi Arabia recorded the highest ASMR rate at 114 (with a range of 92-137) per 100,000. Bulgaria closely followed with a rate of 113 (87-141). In terms of age-standardized DALYs rates, Saudi Arabia again stood out, registering the highest in 1990 with a value of 2573 ( 2069-3145). Evaluating by age groups, 80-84 year old witnessed the most significant death count in 2019 (527,371). Meanwhile, the age group of 65-69 years saw the highest DALYs count in 2019, (10.4 million). Over the last three decades, males consistently experienced higher counts of both deaths and DALYs compared to females. Conclusion: Environmental risk factors contributed to 26.78% of CVD-related deaths and 29% of DALYs, underscoring the critical role of environment in cardiovascular health outcomes in G20 Countries. it's essential to integrate environmental risk assessments into routine check-ups and tailor treatment plans that address specific environmental exposures linked to CVD. There's an urgent need for policy reforms promoting environmental health, coupled with widespread community education about the environmental determinants of cardiovascular diseases.
Abstract P211: Burden and Temporal Trend of Peripheral Artery Disease in the United States and Its Attributable Risk Factors From 1990-2019: An Insights From the Global Burden of Disease Study 2019
Javier, Rafael Cortorreal , Parisapogu, Anusha, Thota, Anjani Kumar, Dadhania, Khush, Gadamidi, Vinay Kumar , Vemparala, Priyatha, Patel, Juhi , Alziadin, Nmair , Desai, Hardik Dineshbhai

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.p211 Get It

Background: Peripheral Artery Disease (PAD) ranks as the 10th primary cause of mortality and the 11th for disability among all cardiovascular diseases in the U.S. Method: We employed the Global Burden of Disease 2019 framework. PAD non-fatal health outcomes were analyzed using the DisMod MR 2.1 (Bayesian meta-regression tool) and determined fatal health outcome with the cause of death ensemble model (CODEm), segmented by age, gender, year, and location from 1990-2019 across the U.S. Results: The annual percentage change (APC) revealed a 26% (9.9-12.4 million) increase in overall prevalence and incidence, a significant 152% (5,757-14,527) rise in deaths, and a 98% (119,253-236,031) uptick in DALYs during 1990-2019. Notably, while the age-standardized incidence rate dipped by 28% (267-193), death and DALY rates climbed by 33% (1.7-2.27) and 11% (36-39) respectively. Delaware witnessed the highest APC in deaths 118% (2.33-5.08) per 100,000, trailed by Colorado with a 58% (35-55) rise in DALYs. Individuals under 70 experienced a 118% (1052-2294) surge in APC for deaths and a 28% (458,357-588,135) increase in incidence. In absolute numbers, males bore a heavier PAD burden, yet females exhibited elevated age-standardized rates from 1990-2019. Conclusion: The study underscores a concerning rise in PAD in the U.S. from 1990-2019, accounted for 1.52% deaths of all cardiovascular related casualties in 2019. Delaware and Colorado have notably high increases in PAD-related outcomes. From both a clinical and public health perspective, addressing high fasting plasma glucose and sodium-rich diets is crucial, as they stand as leading risk factors in PAD's burgeoning prevalence.
Abstract P100: Global Burden of Atrial Fibrillation and Atrial Flutter and Its Trend From 1990-2019 in G20 Countries: Results From the GBD 2019
MADHU, KRUPA, Dadhania, Khush, Banala, Mallareddy , Gadamidi, Vinay Kumar , Thota, Anjani Kumar, VEMPARALA, Priyatha, Parisapogu, Anusha, Patel, Juhi , Alziadin, Nmair , Vemparala, Priyatha, Desai, Hardik Dineshbhai

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.p100 Get It

Background: Atrial Fibrillation and Atrial Flutter (Afib) ranks 6th in mortality and 7th in disability amongst all cardiovascular disease the G20 nations. Method: We employed 2019 Global Burden of Disease methodology. Afib and Flutter, non-fatal health outcomes, such as incidence and prevalence, were estimated using the Bayesian meta-regression tool (DisMod MR 2.1). Fatal health outcomes were assessed using the Cause of Death Ensemble Model (CODEm), considering factors like age, gender, year, and location throughout the G20 from 1990 to 2019. Results: From 1990 to 2019, prevalence rose from 23.2 million (95%UI: 17.6-29.7) to 48.9 million (37.5-61.6). The annual percentage change (APC) in incidence surged by 102% (1.8-3.8 million), DALYs by 119% (3-6 million), and deaths by 168% (93,864-251,272). Despite these increases, the age-standardized rate per 100,000 person-years declined over the past three decades. In 2019, the U.S. reported the highest age-standardized incidence rate at 109.52 (88.97-131.92) per 100,000, while Sweden had the top mortality rate of 8.63 (4-10.32) per 100,000. The age group 65-69 had the peak incidence count of 700,768 (362,032-1,158,177). Meanwhile, the highest death count was in the 85-89 age bracket with 59,325 (48,618-70,077), and the most DALYs were in the 80-84 age group with 1,083,488 (882,995-1,323,533) in 2019. Males consistently faced a higher burden than females over this period. Conclusion: AFib and AF accounted for 1.88% deaths amongst all cardiovascular casualties in 2019. Clinicians in the G20 countries must prioritize early detection and intervention for Afib and flutter, especially in males and the elderly, given its escalating prevalence and its ranking as a major cause of death and disability. Public health strategies in the G20 nations should focus on targeted awareness and interventions to combat the rising burden of atrial fibrillation, with countries like the United States and Sweden requiring heightened attention due to their notably high incidence and mortality rates.